↓ Skip to main content

Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients

Overview of attention for article published in Journal of Pharmaceutical Health Care and Sciences, October 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
Published in
Journal of Pharmaceutical Health Care and Sciences, October 2015
DOI 10.1186/s40780-015-0028-1
Pubmed ID
Authors

Satoru Mitsuboshi, Hitoshi Yamada, Kazuhiko Nagai, Hideo Okajima

Abstract

Febuxostat is a novel xanthine oxidase inhibitor. However, few studies have examined the long-term efficacy and tolerability of febuxostat after switching from allopurinol in hemodialysis (HD) patients. Therefore, the present study evaluated the long-term efficacy and tolerability of febuxostat in HD patients after switching from allopurinol. We monitored the levels of hemoglobin, hematocrit, platelet count, blood urea nitrogen, serum creatinine, serum sodium, serum potassium, serum chloride, serum calcium, serum inorganic phosphorus, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, and total protein that were considered overall as a tolerability index, while the serum uric acid (UA) level was considered an index of efficacy. All values were measured at baseline and at 1, 6, 12, and 16 months after the switch to febuxostat therapy. All subjects switched from allopurinol (100 mg/day) to febuxostat (10 mg/day) in August 2013. Clinical laboratory data were collected at baseline in July 2013 until December 2014. Nine patients were included in the study analysis. Results showed that clinical laboratory data at baseline versus those at 16 months were not significantly different. Serum UA levels, which represented the efficacy index, were significantly different between the baseline level (6.8 ± 1.4) and those at 1, 6, 12, and 16 months (5.2 ± 1.1, 5.1 ± 1.1, 4.6 ± 0.9, and 5.4 ± 1.8 mg/dL, respectively; all p < 0.05). Switching from allopurinol to febuxostat in HD patients reduced serum UA levels, with no changes in other clinical laboratory data in the long term.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 17%
Student > Doctoral Student 2 17%
Researcher 2 17%
Student > Ph. D. Student 2 17%
Other 1 8%
Other 0 0%
Unknown 3 25%
Readers by discipline Count As %
Medicine and Dentistry 5 42%
Nursing and Health Professions 2 17%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Social Sciences 1 8%
Agricultural and Biological Sciences 1 8%
Other 0 0%
Unknown 2 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2015.
All research outputs
#17,420,582
of 21,554,340 outputs
Outputs from Journal of Pharmaceutical Health Care and Sciences
#83
of 127 outputs
Outputs of similar age
#191,042
of 268,392 outputs
Outputs of similar age from Journal of Pharmaceutical Health Care and Sciences
#1
of 1 outputs
Altmetric has tracked 21,554,340 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 127 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,392 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them